Diluted EPS increased 17.2% to $3.47, outperforming revenue growth.
Gross profit margin expanded by 100 basis points to 63.4%.
Aggressive return of capital with $351 million in share repurchases.
Increased utilization of credit facility to fund operations and buybacks.
The Q1 2026 filing presents a company at a crossroads between fundamental operational dominance and aggressive financial engineering. On one hand, the organic growth in diagnostics and the expansion of the premium instrument base provide a durable moat and a predictable revenue engine. The 14.3% revenue increase and the ability to expand gross margins in an inflationary environment are clear indicators of a strong competitive position. However, the divergence between gross profit growth and operating expense growth suggests that the company is spending more to acquire and maintain its market share. The shift toward higher leverage to fund equity buybacks introduces a new risk variable into an otherwise stable business. Investors must now weigh the exceptional quality of the underlying veterinary diagnostics business against a deteriorating cash conversion cycle and a more leveraged balance sheet.